Abstract:Drug-induced liver injury (DILI) is one of the major concerns during drug development. Wide acceptance of the 3 R principles and the innovation of in-vitro techniques have introduced various novel model options, among which the three-dimensional (3D) cell spheroid cultures have shown a promising prospect in DILI prediction. The present study developed a 3D quadruple cell co-culture liver spheroid model for DILI prediction via self-assembly. Induction by phorbol 12-myristate 13-acetate at the concentration of 15.42 ng/mL for 48 hours with a following 24-hour rest period was used for THP-1 cell differentiation, resulting in credible macrophagic phenotypes. HepG2 cells, PUMC-HUVEC-T1 cells, THP-1-originated macrophages, and human hepatic stellate cells were selected as the components, which exhibited adaptability in the designated spheroid culture conditions. Following establishment, the characterization demonstrated the competence of the model in long-term stability reflected by the maintenance of morphology, viability, cellular integration, and cell-cell junctions for at least six days, as well as the reliable liver-specific functions including superior albumin and urea secretion, improved drug metabolic enzyme expression and CYP3A4 activity, and the expression of MRP2, BSEP, and P-GP accompanied by the bile acid efflux transport function. In the comparative testing using 22 DILI-positive and 5 DILI-negative compounds among the novel 3D co-culture model, 3D HepG2 spheroids, and 2D HepG2 monolayers, the 3D culture method significantly enhanced the model sensitivity to compound cytotoxicity compared to the 2D form. The novel co-culture liver spheroid model exhibited higher overall predictive power with margin of safety as the classifying tool. In addition, the non-parenchymal cell components could amplify the toxicity of isoniazid in the 3D model, suggesting their potential mediating role in immune-mediated toxicity. The proof-of-concept experiments demonstrated the capability of the model in replicating drug-induced lipid dysregulation, bile acid efflux inhibition, and α-SMA upregulation, which are the key features of liver steatosis and phospholipidosis, cholestasis, and fibrosis, respectively. Overall, the novel 3D quadruple cell co-culture spheroid model is a reliable and readily available option for DILI prediction.

Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety

Development of novel tools for the in vitro investigation of drug-induced liver injury

Current Perspective: 3D Spheroid Models Utilizing Human-Based Cells for Investigating Metabolism-Dependent Drug-Induced Liver Injury

Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury

Complex in Vitro Model: A Transformative Model in Drug Development and Precision Medicine

Microfluidic human physiomimetic liver model as a screening platform for drug induced liver injury

Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions

Human Hepatic Spheroid Coculture Model for the Assessment of Drug-Induced Liver Injury.

Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI

Current limitations and future opportunities for prediction of DILI from in vitro

In vitro and in silico liver models: Current trends, challenges and opportunities

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury

Liver Extracellular Matrices Bioactivated Hepatic Spheroids as a Model System for Drug Hepatotoxicity Evaluations

A 3D spheroid model of quadruple cell co-culture with improved liver functions for hepatotoxicity prediction

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

Three-dimensional Culture of Hepatocytes for Prediction of Drug-Induced Hepatotoxicity

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Recent advances in the development of in vitro liver models for hepatotoxicity testing

Applications of In Silico Models to Predict Drug-Induced Liver Injury

Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro